Sexually transmitted diseases and infections

QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck

Retrieved on: 
Wednesday, November 18, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Medical devices, Infectious causes of cancer, Clinical medicine, Health, Papillomavirus, Gynaecological cancer, Sexually transmitted diseases and infections, Otorhinolaryngology, Human papillomavirus infection, Qiagen, Cervical cancer, Head and neck cancer, Squamous cell carcinoma

The assay will detect the presence of HPV genotypes and will be developed on QIAGENs RGQ MDx platform, a member of the QIAsymphony family of products.

Key Points: 
  • The assay will detect the presence of HPV genotypes and will be developed on QIAGENs RGQ MDx platform, a member of the QIAsymphony family of products.
  • QIAGEN plans to expand the panel for use across HPV-driven cancers such as cervical cancer and other cancers, in order to provide a universal HPV companion diagnostic (CDx) for QIAGENs pharmaceutical partners.
  • Head and neck squamous cell carcinoma is the sixth most common cancer.
  • Every year, there are more than 650,000 cases leading to 330,000 deaths, according to a 2018 global cancer study.

PointClickCare Helps Senior Care Providers Enforce Best Practices for Antibiotic Stewardship Through the Use of the Infection Prevention & Control Solution

Retrieved on: 
Wednesday, November 18, 2020
Data management, Technology, Managed care, Health, General Health, Seniors, Software, Networks, Internet, Mobile, Wireless, Consumer, Health sciences, Articles, Health, Antibiotic resistance, Pharmaceuticals policy, Veterinary medicine, Evolutionary biology, Sexually transmitted diseases and infections, Antimicrobial resistance, Antimicrobial stewardship, Antibiotic misuse, Antibiotic

A clinical workflow and intelligence solution that helps care teams perform ongoing resident surveillance, the commercial release of Infection Prevention & Control achieves the next milestone to help our customers proactively manage and control the spread of infection amongst the senior population.

Key Points: 
  • A clinical workflow and intelligence solution that helps care teams perform ongoing resident surveillance, the commercial release of Infection Prevention & Control achieves the next milestone to help our customers proactively manage and control the spread of infection amongst the senior population.
  • According to the World Health Organization , misuse and overuse of antibiotics are among of the main drivers of antibiotic resistance.
  • As such, antibiotic stewardship, defined as interventions designed to optimize antibiotic use, is part of the key actions of their Global Action Plan on Antimicrobial Resistance .
  • Common infections, such as pneumonia, tuberculosis, gonorrhea, and salmonellosis, are becoming harder to treat due to antibiotic resistance.

Evofem Biosciences to Present at Stifel Virtual Healthcare Conference

Retrieved on: 
Thursday, November 12, 2020
Chlamydiae, Sexually transmitted diseases and infections, Infectious causes of cancer, Infections with a predominantly sexual mode of transmission, Medical specialties, Chlamydia trachomatis, Infectious diseases, Chlamydia, Clinical medicine

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m.

Key Points: 
  • SAN DIEGO, Nov. 12, 2020 /PRNewswire/ --Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m.
  • To access the live and archived webcast of this fireside chat, visit the Investors section of the Evofem Biosciences website at www.evofem.com , and select the Events and Presentations tab.
  • The Company is evaluating EVO100 in aPhase 3 clinical trial,' EVOGUARD ,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeaeinfection in women.
  • Phexxi is a trademark of Evofem Biosciences, Inc.

Mycoplasma Testing Market worth $1,095 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, November 11, 2020
Sexually transmitted diseases and infections, Mollicutes, Infectious causes of cancer, Bacterial vaginosis, Infertility, Mycoplasma, Mycoplasmataceae, Natural sciences, Assay, Taxa

The assays, kits, & reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service segment, in 2019

Key Points: 
  • The assays, kits, & reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service segment, in 2019
    The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service.
  • Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing.
  • Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136509856
    The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World.
  • In 2019, North America accounted for the largest share of the global mycoplasma testing market.

Mycoplasma Testing Market worth $1,095 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, November 11, 2020
Sexually transmitted diseases and infections, Mollicutes, Infectious causes of cancer, Bacterial vaginosis, Infertility, Mycoplasma, Mycoplasmataceae, Natural sciences, Assay, Taxa

The assays, kits, & reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service segment, in 2019

Key Points: 
  • The assays, kits, & reagents products segment accounted for the largest share of the mycoplasma testing market, by product & service segment, in 2019
    The mycoplasma testing market is segmented into assays, kits, & reagents; instruments; and services based on product & service.
  • Based on application, the mycoplasma testing market is segmented into cell line testing, virus testing, and end-of-production cell testing.
  • Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=136509856
    The global mycoplasma testing market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World.
  • In 2019, North America accounted for the largest share of the global mycoplasma testing market.

Global Mycoplasma Testing Market Size by Product, by Geographic Scope, by End-user, and Forecast

Retrieved on: 
Tuesday, November 10, 2020
Other Manufacturing, Medical devices, Medical Supplies, Clinical trials, Manufacturing, Other Health, Biotechnology, Health, Science, Other Science, Articles, Business process, Sexually transmitted diseases and infections, Bacterial vaginosis, Infertility, Mycoplasma, Market analysis, Market research, Trend

The mycoplasma testing market is poised to grow by USD 445.57 million during 2020-2024, progressing at a CAGR of over 11% during the forecast period.

Key Points: 
  • The mycoplasma testing market is poised to grow by USD 445.57 million during 2020-2024, progressing at a CAGR of over 11% during the forecast period.
  • View the full release here: https://www.businesswire.com/news/home/20201110005757/en/
    Technavio has announced its latest market research report titled Global Mycoplasma Testing Market 2020-2024 (Graphic: Business Wire)
    Worried about Your Business amidst COVID-19 Impact?
  • The report on the mycoplasma testing market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The mycoplasma testing market analysis includes product segment and geography landscape.

Chlamydia Infections Pipeline Review 2020: Therapeutics Development, Assessment and Drug Profiles - ResearchAndMarkets.com

Retrieved on: 
Monday, November 9, 2020
Health, General Health, Chlamydiae, Sexually transmitted diseases and infections, Infectious causes of cancer, Epidemiology, Chlamydia, Medical specialties, Infection, Clinical medicine, Infections with a predominantly sexual mode of transmission, Medicine, Chlamydia research

The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.

Key Points: 
  • The Chlamydia Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Chlamydia Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide evaluates Chlamydia Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • Formulate corrective measures for pipeline projects by understanding Chlamydia Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress

Retrieved on: 
Monday, November 9, 2020
Health, Genetics, Clinical trials, General Health, Pharmaceutical, Biotechnology, Sexually transmitted diseases and infections, Medical specialties, Virology, Biology of bipolar disorder, Herpes simplex, Organ systems, Herpes

Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today reported financial results and key operational progress updates for the third quarter ended September 30, 2020.

Key Points: 
  • Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today reported financial results and key operational progress updates for the third quarter ended September 30, 2020.
  • Financial results for the quarter ended September 30, 2020
    Cash, cash equivalents and short-term investments totaled $286.4 million on September 30, 2020.
  • Research and development expenses for the third quarter ended September 30, 2020 were $5.1 million, compared to $3.9 million for third quarter 2019.
  • For additional information on the Companys financial results for the third quarter ended September 30, 2020, refer to form 10-Q filed with the SEC.

New Data Presented at the European Academy of Dermatology and Venereology (EADV) 29th Congress

Retrieved on: 
Saturday, October 31, 2020
Sexually transmitted diseases and infections, Medicine, Medical specialties, Health care, Venereology, European Board of Dermatology-Venereology, Draft:Jacek Szepietowski

Presented at the 29th EADV (European Association of Dermatology and Venereology) Virtual Congress 2020.

Key Points: 
  • Presented at the 29th EADV (European Association of Dermatology and Venereology) Virtual Congress 2020.
  • Presented at the 29th EADV (European Association of Dermatology and Venereology) Virtual Congress 2020.
  • Presented at the 29th EADV (European Association of Dermatology and Venereology) Virtual Congress 2020.
  • Presented at the 29th EADV (European Association of Dermatology and Venereology) Virtual Congress 2020.

LEO Pharma Presents Data for Tralokinumab on Pooled Safety, S. aureus Colonization Reduction and Impact on Vaccine Response Rates at the 29th Annual European Academy of Dermatology and Venereology (EADV) Virtual Congress

Retrieved on: 
Thursday, October 29, 2020
Health, FDA, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Sexually transmitted diseases and infections, Venereology, Dermatology, Medicine, Clinical medicine, Health care, Draft:Hessa Al Buainian, Draft:Jacek Szepietowski, ECZTRA 1, 2, ECZTRA 3, ECZTRA 5 and Phase 2b Trials, atopic dermatitis, tralokinumab, LEO Pharma

LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

Key Points: 
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.
  • E-poster at European Academy of Dermatology and Venereology (EADV) Virtual Congress; October 29-31, 2020.
  • Oral presentation at European Academy of Dermatology and Venereology (EADV) Virtual Congress; October 29-31, 2020.
  • E-poster at European Academy of Dermatology and Venereology (EADV) Virtual Congress; October 29-31, 2020.